Medsender has raised $5.0M in total across 1 funding round.
Medsender's investors include Altair Capital Management, Ballast Point Ventures, B Capital Group, DNX Ventures, IDG Ventures, Alexander Rosen, Thayer Ventures, Erik Blachford, Vivek Garipalli.
Medsender is a New York-based healthcare technology company founded in 2021 that builds an AI-powered workflow automation platform to streamline administrative tasks for medical practices, hospitals, pharmacies, and healthcare organizations.[1][3][4] Its flagship product, the AI Medical Assistant® (MAIRA™), automates front-office operations including secure HIPAA-compliant faxing, AI-driven document processing, referral management, scheduling, and virtual receptionist services via a human-like AI voice agent.[1][3][4] Medsender serves thousands of providers across all 50 U.S. states, integrating seamlessly with electronic health records (EHR/EMR) systems to extract data from unstructured sources like faxes, emails, and calls, reducing manual work by up to 80% and enabling same-day referral processing.[2][4][7] The company demonstrates strong growth momentum, ranking #550 on the 2025 Inc. 5000 list of America's fastest-growing private companies.[1]
Medsender emerged from the vision of modernizing outdated healthcare communication, particularly the persistent reliance on fax machines and paper-based systems for sharing medical records.[5][8] Co-founders include Salman Haque (Co-CEO), who highlighted how unstructured data burdens patients and providers, Qayyum (initial driver with a goal to eliminate faxing), and Mahmoud Tohmaz (CTO), a technology expert who helped pivot the platform toward AI automation.[8] Launched in 2021 on Google Cloud, the company started as a digital fax solution but evolved rapidly with AI advancements; its first AI tool in 2021 used Vertex AI for document extraction, categorization, and workflow optimization, marking a pivotal shift to comprehensive automation.[1][8] Early traction came from addressing real pain points in administrative workflows, leading to adoption by small clinics and enterprise organizations alike.[8]
Medsender rides the wave of AI-driven healthcare automation, targeting the trillion-dollar U.S. healthcare admin sector where faxing still dominates 90% of communications despite digital alternatives, exacerbated by unstructured data silos.[5][8] Its timing aligns with surging AI adoption post-2021 advancements in generative AI and cloud tools like Google Vertex AI, enabling compliance-heavy innovations amid labor shortages and rising operational costs.[4][8] Market forces favoring Medsender include regulatory pushes for HIPAA-secure tech, EHR interoperability mandates, and post-pandemic demand for efficient patient intake/referrals, positioning it to disrupt legacy systems.[2][5] By automating workflows, it influences the ecosystem by boosting provider efficiency, improving patient outcomes through faster care coordination, and enabling health tech firms to scale via its API, as seen in case studies automating tens of thousands of faxes monthly.[1][9]
Medsender is poised for accelerated expansion with ongoing MAIRA enhancements (e.g., June 2025 upgrade for deeper EHR integrations and voice realism) and enterprise AI scaling, potentially capturing more of the fragmented healthcare comms market.[4][8] Trends like multimodal AI, real-time PHI analytics, and regulatory tailwinds for automation will propel it, evolving from fax replacement to a full AI orchestration layer for practices.[3][5] Its influence may grow by powering health tech partnerships and international expansion, turning admin drudgery into a competitive edge—much like how it began by reimagining faxing as an advantage.[8][9]
Medsender has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $5.0M Series A | Altair Capital Management, Ballast Point Ventures, B Capital Group, DNX Ventures, IDG Ventures, Alexander Rosen, Thayer Ventures, Erik Blachford, Vivek Garipalli |
